600789 鲁抗医药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入3,279,4832.93%6,146,7215,621,4424,923,7844,205,109
减:营业总成本3,176,5243.55%5,907,6645,455,3694,793,3894,142,309
    其中:营业成本2,543,3501.95%4,631,2684,373,9623,746,1053,224,977
               财务费用24,02365.66%66,63978,20168,15967,741
               资产减值损失(4,864)-80.94%(54,682)(41,938)(30,942)(22,030)
公允价值变动收益(153)-348.00%(69)52113(57)
投资收益(3,878)95.30%(7,134)(6,582)(3,296)2,598
    其中:对联营企业和合营企业的投资收益(3,878)95.30%(7,169)(6,611)(3,295)2,481
营业利润320,166114.71%272,133148,774116,019264,885
利润总额320,915114.73%272,975150,095113,579262,161
减:所得税费用14,2053.51%16,1886,98023,68728,676
净利润306,711125.98%256,787143,11589,891233,485
减:非控股权益6,74855.20%10,6155,1027935,608
股东净利润299,962128.32%246,172138,01389,099227,877

市场价值指针
每股收益 (元) *0.330120.00%0.2800.1600.1000.260
每股派息 (元) *0.020--0.0900.0550.0500.055
每股净资产 (元) *4.2959.07%4.0313.7853.6953.651
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容